– USA, CA – Iambic Therapeutics, a clinical-stage biotechnology company developing novel therapeutics using its unique AI-driven discovery platform, announced the appointment of Dr. Mary Tagliaferri (M.D.) to its Board of Directors.
About Dr. Mary Tagliaferri
A biotech industry veteran, Dr. Tagliaferri is CMO at Nektar Therapeutics, where she heads clinical development strategy for the company’s immuno-oncology portfolio, as well as strategic alliances, and medical affairs.
Prior to joining Nektar, Dr. Tagliaferri was a clinical and regulatory consultant to InterMune, served as CMO at KangLaiTe USA, and was Co-Founder and President and CMO of BioNovo, where she led the company’s clinical drug development strategy and global regulatory affairs. In 2012, Dr. Tagliaferri received the State of California Woman of the Year award for her advancements of clinical research in women’s health and her mentorship of women in the biotechnology field. She received her B.S. degree from Cornell University and her M.D. from the University of California, San Francisco.
About the Iambic Therapeutics Physics-Informed AI-Driven Discovery Platform
The Iambic Therapeutics AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Iambic NeuralPLexer, which provides state-of-the-art structural predictions of protein-ligand complexes. The integration of physics principles into the platform’s AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform’s algorithms enable identification of new chemical mechanisms for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic windows, and exploration of the chemical space to discover candidates for development with highly differentiated properties. Through close integration of AI-generated molecular designs with automated experimental execution, Iambic completes design-make-test cycles on a weekly cadence.
About Iambic Therapeutics
Founded in 2019 and headquartered in San Diego, California, Iambic Therapeutics is disrupting the therapeutics landscape with its unique AI-driven drug-discovery platform. Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters with strong track records of success in delivering clinically validated therapeutics. The Iambic platform has been demonstrated to deliver high-quality, differentiated therapeutics to clinical stage with unprecedented speed and across multiple target classes and mechanisms of action. The Iambic team is advancing an internal pipeline of clinical assets to address urgent unmet patient needs.
For more information : https://www.iambic.ai/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.